Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
Adenocarcinoma
/ genetics
Adenosine Triphosphatases
/ genetics
Aged
Biomarkers, Tumor
/ analysis
Chromatin Assembly and Disassembly
Cohort Studies
DNA Helicases
/ genetics
DNA-Binding Proteins
/ genetics
Esophageal Neoplasms
/ genetics
Female
Humans
Immunohistochemistry
Kaplan-Meier Estimate
Loss of Function Mutation
Male
Middle Aged
Multivariate Analysis
Nuclear Proteins
/ genetics
Prognosis
SMARCB1 Protein
/ genetics
Transcription Factors
/ genetics
Tumor Suppressor Protein p53
/ genetics
Heterogeneity
Loss-of-function
Oesophageal adenocarcinoma
SWI/SNF-complex
TP53 loss
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
06 Jan 2020
06 Jan 2020
Historique:
received:
25
05
2019
accepted:
03
12
2019
entrez:
8
1
2020
pubmed:
8
1
2020
medline:
17
6
2020
Statut:
epublish
Résumé
The SWI/SNF complex is an important chromatin remodeler, commonly dysregulated in cancer, with an estimated mutation frequency of 20%. ARID1A is the most frequently mutated subunit gene. Almost nothing is known about the other familiar members of the SWI/SNF complexes, SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1), in oesophageal adenocarcinoma (EAC). We analysed a large cohort of 685 patients with EAC. We used four different antibodies to detect a loss-of-protein of ARID1A BRM, BRG1 and INI1 by immunohistochemistry and correlated these findings with molecular and clinical data. Loss of ARID1A, BRG1, BRM and INI1 was observed in 10.4, 3.4, 9.9 and 2% of EAC. We found a co-existing protein loss of ARID1A and BRM in 9.9% and of ARID1A and BRG1 in 2.2%. Patients with loss of ARID1A and TP53 wildtype EACs showed a shortened overall survival compared with AIRDA1A-positive tumours [median overall survival was 60.1 months (95%CI 1.2-139.9 months)] in patients with ARIDA-1A expression and 26.2 months (95%CI 3.7-19.1 months) in cases of ARIDA-1A loss (p = 0.044). Tumours with loss or expression of ARID1A and TP53 loss were not associated with a difference in survival. Only one tumour revealed high microsatellite instability (MSI-H) with concomitant ARID1A loss. All other ARID1A loss-EACs were microsatellite-stable (MSS). No predictive relevance was seen for SWI/SNF-complex alterations and simultaneous amplification of different genes (PIK3CA, KRAS, c-MYC, MET, GATA6, ERBB2). Our work describes, for the first time, loss of one of the SWI/SNF ATPase subunit proteins in a large number of adenocarcinomas of the oesophagus. Several papers discuss possible therapeutic interventions for tumours showing a loss of function of the SWI/SNF complex, such as PARP inhibitors or PI3K and AKT inhibitors. Future studies will be needed to show whether SWI/SNF complex-deficient EACs may benefit from personalized therapy.
Sections du résumé
BACKGROUND
BACKGROUND
The SWI/SNF complex is an important chromatin remodeler, commonly dysregulated in cancer, with an estimated mutation frequency of 20%. ARID1A is the most frequently mutated subunit gene. Almost nothing is known about the other familiar members of the SWI/SNF complexes, SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1), in oesophageal adenocarcinoma (EAC).
METHODS
METHODS
We analysed a large cohort of 685 patients with EAC. We used four different antibodies to detect a loss-of-protein of ARID1A BRM, BRG1 and INI1 by immunohistochemistry and correlated these findings with molecular and clinical data.
RESULTS
RESULTS
Loss of ARID1A, BRG1, BRM and INI1 was observed in 10.4, 3.4, 9.9 and 2% of EAC. We found a co-existing protein loss of ARID1A and BRM in 9.9% and of ARID1A and BRG1 in 2.2%. Patients with loss of ARID1A and TP53 wildtype EACs showed a shortened overall survival compared with AIRDA1A-positive tumours [median overall survival was 60.1 months (95%CI 1.2-139.9 months)] in patients with ARIDA-1A expression and 26.2 months (95%CI 3.7-19.1 months) in cases of ARIDA-1A loss (p = 0.044). Tumours with loss or expression of ARID1A and TP53 loss were not associated with a difference in survival. Only one tumour revealed high microsatellite instability (MSI-H) with concomitant ARID1A loss. All other ARID1A loss-EACs were microsatellite-stable (MSS). No predictive relevance was seen for SWI/SNF-complex alterations and simultaneous amplification of different genes (PIK3CA, KRAS, c-MYC, MET, GATA6, ERBB2).
CONCLUSION
CONCLUSIONS
Our work describes, for the first time, loss of one of the SWI/SNF ATPase subunit proteins in a large number of adenocarcinomas of the oesophagus. Several papers discuss possible therapeutic interventions for tumours showing a loss of function of the SWI/SNF complex, such as PARP inhibitors or PI3K and AKT inhibitors. Future studies will be needed to show whether SWI/SNF complex-deficient EACs may benefit from personalized therapy.
Identifiants
pubmed: 31906887
doi: 10.1186/s12885-019-6425-3
pii: 10.1186/s12885-019-6425-3
pmc: PMC6945480
doi:
Substances chimiques
ARID1A protein, human
0
Biomarkers, Tumor
0
DNA-Binding Proteins
0
Nuclear Proteins
0
SMARCA2 protein, human
0
SMARCB1 Protein
0
SMARCB1 protein, human
0
TP53 protein, human
0
Transcription Factors
0
Tumor Suppressor Protein p53
0
Adenosine Triphosphatases
EC 3.6.1.-
SMARCA4 protein, human
EC 3.6.1.-
DNA Helicases
EC 3.6.4.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
12Références
Surg Case Rep. 2019 Jan 16;5(1):8
pubmed: 30649642
BMC Cancer. 2019 Jan 8;19(1):38
pubmed: 30621632
BMC Cancer. 2014 Feb 22;14:120
pubmed: 24559118
Nat Rev Mol Cell Biol. 2007 May;8(5):369-78
pubmed: 17377526
Pharmacol Ther. 2018 Oct;190:15-23
pubmed: 29730444
Nat Genet. 2012 May;44(5):570-4
pubmed: 22484628
Annu Rev Biochem. 2009;78:273-304
pubmed: 19355820
Cancer Cell. 2019 Feb 11;35(2):177-190.e8
pubmed: 30686770
Virchows Arch. 2012 Oct;461(4):367-77
pubmed: 22915242
Mol Cell. 1999 Feb;3(2):247-53
pubmed: 10078207
Nat Med. 2018 May;24(5):556-562
pubmed: 29736026
Oncotarget. 2017 Dec 11;8(70):115179-115189
pubmed: 29383151
Nat Genet. 2011 Oct 30;43(12):1219-23
pubmed: 22037554
Clin Cancer Res. 2015 Feb 15;21(4):907-15
pubmed: 25492085
Br J Cancer. 1997;75(9):1336-9
pubmed: 9155055
Nat Genet. 2013 May;45(5):478-86
pubmed: 23525077
Methods Mol Med. 2005;114:257-68
pubmed: 16156109
Arch Pathol Lab Med. 2017 Jul;141(7):970-977
pubmed: 28440661
Oncotarget. 2014 Jul 30;5(14):5295-303
pubmed: 24979463
J Pathol. 2013 Nov;231(3):301-10
pubmed: 24308032
Ann Surg. 2007 Feb;245(2):241-6
pubmed: 17245177
Nat Med. 2014 Mar;20(3):251-4
pubmed: 24562383
World J Gastroenterol. 2015 Feb 21;21(7):2159-68
pubmed: 25717252
Genes Chromosomes Cancer. 2007 Aug;46(8):745-50
pubmed: 17492758
Hum Mutat. 2012 Jan;33(1):100-3
pubmed: 22009941
Oncogene. 2009 Apr 9;28(14):1653-68
pubmed: 19234488
J Mol Biol. 1984 Oct 5;178(4):853-68
pubmed: 6436497
PLoS One. 2013;8(1):e55119
pubmed: 23355908
Cancer Res. 2003 Feb 1;63(3):560-6
pubmed: 12566296
Cancer Biol Ther. 2014 Jun 1;15(6):655-64
pubmed: 24618703
Transl Oncol. 2019 Jan;12(1):154-161
pubmed: 30317074
Nat Med. 2015 Mar;21(3):231-8
pubmed: 25686104
Virchows Arch. 2018 Jan;472(1):43-54
pubmed: 29500519
Pathologe. 2010 May;31(3):208-17
pubmed: 20443098
Cold Spring Harb Symp Quant Biol. 2016;81:53-60
pubmed: 28408647
Int J Cancer. 2004 Nov 20;112(4):636
pubmed: 15382044
Oncotarget. 2016 Apr 19;7(16):21763-74
pubmed: 26943575
Cancer Discov. 2015 Jul;5(7):752-67
pubmed: 26069190
Cancer Genet Cytogenet. 2005 Feb;157(1):82-6
pubmed: 15676154
Eur J Cancer. 2018 May;94:104-114
pubmed: 29550565
Genetics. 1984 Dec;108(4):845-58
pubmed: 6392017
Oncogene. 2014 Jan 16;33(3):347-57
pubmed: 23318448
Ann Surg. 2008 Dec;248(6):902-8
pubmed: 19092334
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
J Cancer Res Clin Oncol. 2018 Sep;144(9):1731-1739
pubmed: 29974234
Cancer Genet Cytogenet. 2008 Feb;181(1):31-5
pubmed: 18262050
Oncogene. 2002 Feb 14;21(8):1196-207
pubmed: 11850839
Cancer Res. 2019 May 15;79(10):2761-2774
pubmed: 30877105
Genome Res. 2012 Nov;22(11):2120-9
pubmed: 23028188